{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:43:08Z","timestamp":1786113788020,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005614","name":"BC Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.radonc.2026.111532","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:45:48Z","timestamp":1778888748000},"page":"111532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-6197","authenticated-orcid":false,"given":"Robert","family":"Olson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3938-3279","authenticated-orcid":false,"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanah","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6420-1510","authenticated-orcid":false,"given":"Hadassah","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Carolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-6445","authenticated-orcid":false,"given":"Will","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-340X","authenticated-orcid":false,"given":"Fred","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-7096","authenticated-orcid":false,"given":"Stacy","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7128","authenticated-orcid":false,"given":"Siavash","family":"Atrchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0611-539X","authenticated-orcid":false,"given":"Angela","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Berrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3861-7378","authenticated-orcid":false,"given":"Deepa","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ante","family":"Mestrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-450X","authenticated-orcid":false,"given":"Howard","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Valev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-4230","authenticated-orcid":false,"given":"Shilo","family":"Lefresene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tyldesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111532_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111532_b0010","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ijrobp.2008.03.044","article-title":"Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy","volume":"72","author":"Milano","year":"2008","journal-title":"Int J Radiation Oncol* Biol* Phys"},{"key":"10.1016\/j.radonc.2026.111532_b0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111532_b0020","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111532_b0025","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.21037\/atm-21-1116","article-title":"Current usage of stereotactic body radiotherapy for oligometastatic prostate cancer in korea: patterns of care survey (KROG 19-08)","volume":"9","author":"Bae","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.radonc.2026.111532_b0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111532_b0035","doi-asserted-by":"crossref","unstructured":"Franzese C, Tanadini-Lang S, Verellen D, et al: Clinical practice, barriers to implementation, and priorities for equitable access of stereotactic body radiation therapy: An analysis of the global status by the ESTRO SBRT focus group. Clin Transl Radiation Oncol 57, 2025.","DOI":"10.2139\/ssrn.5818012"},{"key":"10.1016\/j.radonc.2026.111532_b0040","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(19)32494-8","article-title":"Points to consider regarding the SABR-COMET trial","volume":"395","author":"Macbeth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111532_b0045","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111532_b0050","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111532_b0055","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5","volume":"18","author":"Olson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111532_b0060","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: primary toxicity results of the SABR-5 trial","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111532_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2026.01.012","article-title":"Treatment with stereotactic ablative radiotherapy for patients with up to 5 oligometastatic cancer lesions: long-term outcomes of the nonrandomized population-based phase 2 SABR-5 clinical trial","author":"Leclerc","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111532_b0070","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111532_b0075","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2013.50.1411","article-title":"Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score","volume":"31","author":"Sahgal","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111532_b0080","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/cancers15102839","article-title":"Clinical outcomes of patients with metastatic breast cancer treated with hypo-fractionated liver radiotherapy","volume":"15","author":"Mushonga","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111532_b0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12885-024-11905-7","article-title":"Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases\/progression: SIMPLIFY-SABR-COMET","volume":"24","author":"Olson","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111532_b0090","article-title":"Enthusiasm and equipoise as definitive evidence emerges in oligometastatic SABR","author":"Olson","year":"2026","journal-title":"Int J Radiation Oncol* Biol* Phys"},{"key":"10.1016\/j.radonc.2026.111532_b0095","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ijrobp.2024.01.008","article-title":"Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the phase 2 SABR-5 trial","volume":"118","author":"Baker","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026003713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026003713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T19:54:37Z","timestamp":1785959677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026003713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"alternative-id":["S0167814026003713"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111532","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111532"}}